NEW YORK (GenomeWeb) – Nanopore-based sequencing firm Quantapore today announced it closed a Series B financing round raising up to $35 million.

The Menlo Park, Calif.-based firm did not disclose the name of the investors but said that the funds will go toward finalizing the development of its sequencing technology and commercializing its platform.

The final amount of the raise will depend on whether Quantapore meets certain milestones before all funds are released, Quantapore CEO Martin Huber said in an email.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.